The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

convergencepharma.com

Stage

Dead | Dead

Total Raised

$35.4M

About Convergence Pharmaceuticals

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (‚GSK‚). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels. Convergence Pharmaceuticals is well funded and raised $35.4 million in Series A financing from a syndicate of leading European and US VCs.

Convergence Pharmaceuticals Headquarter Location

Maia Building Babraham Research Campus

Cambridge, England, CB22 3AT,

United Kingdom

+44-(0)1223-755-501

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Convergence Pharmaceuticals Patents

Convergence Pharmaceuticals has filed 21 patents.

The 3 most popular patent topics include:

  • Calcium channel blockers
  • Ion channels
  • Amines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/2/2015

12/3/2019

Prodrugs, Amines, Pyridines, Carboxylate esters, Fluoroarenes

Grant

Application Date

10/2/2015

Grant Date

12/3/2019

Title

Related Topics

Prodrugs, Amines, Pyridines, Carboxylate esters, Fluoroarenes

Status

Grant

Latest Convergence Pharmaceuticals News

Global Trigeminal Neuralgia (Tic Douloureux) Pipeline Review 2020: Therapeutic Analysis Report – 10 Companies & 3 Drug Profiles – ResearchAndMarkets.com

Oct 13, 2020

Trigeminal Neuralgia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Trigeminal Neuralgia (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 4, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Trigeminal Neuralgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Central Nervous System). The pipeline guide reviews pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Trigeminal Neuralgia (Central Nervous System) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Trigeminal Neuralgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System) Reasons to Buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline. Key Topics Covered: Trigeminal Neuralgia (Tic Douloureux) – Product Development Milestones Featured News & Press Releases Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial Sep 23, 2014: Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802 Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia Appendix Contacts

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.